Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with
AIM ImmunoTech Inc. says Ampligen data supports synergistic potential with checkpoint blockade therapies proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
AIM ImmunoTech Inc. says Ampligen data supports synergistic potential with checkpoint blockade therapies proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.